December 18, 2008 - Therapeutic strategies that use neoadjuvant RT for patients with resectable pancreatic cancer showed a survival benefit over surgery alone or surgery with adjuvant RT in treating pancreatic cancer, according to a study published in the November 2008 issue of the International Journal of Radiation Oncology Biology Physics.

Cancer of the exocrine pancreas is the fifth leading cause of cancer death in the U.S. Neoadjuvant chemoradiation has been investigated in several trials as a strategy for downstaging locally advanced disease to resectability.

The aim of the study was to examine the effect of neoadjuvant radiation therapy (RT) versus other treatments on long-term survival for patients with resectable pancreatic cancer in a large population-based sample group.

The Surveillance, Epidemiology and End Results (SEER) registry database (1994–2003) was queried for cases of surgically resected pancreatic cancer. Retrospective analysis was performed. The endpoint of the study was overall survival.

Using Kaplan-Meier analysis, the researchers found that the median overall survival of patients receiving neoadjuvant RT was 23 months versus 12 months with no RT and 17 months with adjuvant RT. Using Cox regression and controlling for independent covariates (age, sex, stage, grade, and year of diagnosis), the researchers found that neoadjuvant RT results in significantly higher rates of survival than other treatments (hazard ratio [HR], 0.55; 95 percent confidence interval, 0.38–0.79; p = 0.001). Specifically comparing adjuvant with neoadjuvant RT, results showed a significantly lower HR for death in patients receiving neoadjuvant RT rather than adjuvant RT (HR, 0.63; 95 percent confidence interval, 0.45–0.90; p = 0.03).

This analysis of SEER data showed a survival benefit for the use of neoadjuvant RT over surgery alone or surgery with adjuvant RT in treating pancreatic cancer. Therapeutic strategies that use neoadjuvant RT should be further explored for patients with resectable pancreatic cancer.

For more information: www.redjournal.org


Related Content

News

Aug. 5, 2024 — Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that adding ...

Time August 09, 2024
arrow
News | Radiology Business

July 31, 2024 — The American Registry of Radiologic Technologists (ARRT) announced the three Registered Technologists (R ...

Time July 31, 2024
arrow
News | PET-CT

July 31, 2024 — In a head-to-head comparison with FDG PET/CT, FDG PET/MRI demonstrated comparable or superior diagnostic ...

Time July 31, 2024
arrow
Feature | Radiation Oncology | By Christine Book

News emerging from several leading organizations and vendors in the radiation therapy arena came in at a fast pace in ...

Time July 30, 2024
arrow
News | Radiopharmaceuticals and Tracers

July 24, 2024 — Telix Pharmaceuticals Limited announced that the United States (U.S.) Food and Drug Administration (FDA) ...

Time July 24, 2024
arrow
News | Radiation Therapy

July 22, 2024 — RefleXion Medical, an external-beam theranostic oncology company, today announced that researchers from ...

Time July 22, 2024
arrow
News | ASTRO

July 18, 2024 — The members of the American Society for Radiation Oncology (ASTRO) recently elected five new officers to ...

Time July 18, 2024
arrow
News | PET-CT

July 16, 2024 — A new research paper was published in Oncotarget's Volume 15 on June 20, 2024, titled, “Comparison of ...

Time July 16, 2024
arrow
News | Digital Pathology

July 12, 2024 — AGFA HealthCare, a global leader in healthcare imaging management solutions, announced that Enterprise ...

Time July 12, 2024
arrow
News | Digital Pathology

July 12, 2024 — Diagnosing cancer and providing the personalized therapy it often requires, is a collaborative effort ...

Time July 12, 2024
arrow
Subscribe Now